emapalumab-lzsg
Gamifant
Pharmaceutical company: Swedish Orphan Biovitrum
NEW INDICATION & DOSAGE
Hemophagocytic lymphohistiocytosis and macrophage activation syndrome with known or suspected Still disease (including systemic juvenile idiopathic arthritis) in patients with refractory or recurrent disease or intolerance to steroids
Adults and children: Initially, 6 mg/kg IV, followed by 3 mg/kg every 3 days for 5 doses, and then 3 mg/kg twice weekly.
Adjust-a-dose: If poor clinical response, may titrate to maximum cumulative dose of 10 mg/kg over 3 days and increase frequency to every 2 days or daily. See manufacturer's instructions for further dosing increases. If condition improves, consider decreasing dose to previous level. Consider stopping drug if condition doesn't stabilize with maximum dosage.
Released: September 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
finerenone
Kerendia
Pharmaceutical company: Bayer HealthCare Pharmaceuticals
NEW INDICATION & DOSAGE
Reduce risk of CV death, hospitalization for HF, and urgent HF visits in patients with HF with LVEF of 40% or more
Adults: Dosage based on eGFR and serum potassium thresholds. Don't initiate drug for eGFR less than 25 mL/minute/1.73 m2 or serum potassium level more than 5.0 mEq/L. For eGFR 60 mL/minute/1.73 m2 or more, start at 20 mg daily with target dosage of 40 mg daily. For eGFR 25 to less than 60 mL/minute/1.73 m2, start at 10 mg daily with target dosage of 20 mg daily. After 4 weeks, increase dosage, maintain current dosage, or withhold drug per manufacturer's instructions. Measure eGFR and serum potassium 4 weeks after dosage adjustment, and periodically during therapy; adjust dose as needed.
Released: September 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.